NewsBenzingaB. Riley Securities maintient son avis d'achat sur Elicio Therapeutics, mais abaisse l'objectif de prix à 8 $. B. Riley Securities maintient son avis d'achat sur Elicio Therapeutics, mais abaisse l'objectif de prix à 8 $. Benzinga 2026.09.24 14:16 (GMT+0) Open on Benzinga Other news If You Invested $1000 In American International Gr Stock 5 Years Ago, You Would Have This Much Today BNP Paribas And Google Cloud Announce Five-Year Agentic AI And Cloud Partnership; Terms Not Disclosed These Analysts Revise Their Forecasts On Paychex Following Q1 Results Carnival Analysts Cut Price Targets Ahead of Q3 Earnings Lilly Wins FDA Nod For Weekly Insulin, Signs $3.25 Billion InnoCare Pact Meet the next wave of VCs judging Startup Battlefield 200 at TechCrunch Disrupt 2026
BNP Paribas And Google Cloud Announce Five-Year Agentic AI And Cloud Partnership; Terms Not Disclosed
